Immunity Factors in Cancer Colon Patients Clinical Trial
— tumorimmunityOfficial title:
Effect of Epidural-inhalational Versus Epidural-intravenous Anaesthesia on Anti-tumor Immunity in Patients Undergoing Open Surgery for Cancer Colon
NCT number | NCT04518579 |
Other study ID # | 375 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 15, 2018 |
Est. completion date | August 1, 2020 |
Verified date | August 2020 |
Source | South Egypt Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Surgery is the primary treatment for colon cancer. However, the rate of recurrence or metastasis in colon cancer can be as high as 30%, even in stages 1 and 2 . Most colon cancer-related deaths are caused by metastatic disease . Many patients with colon cancer harbour micrometastases and disseminated tumour cells at the time of surgery . Whether the micrometastases develop into clinically significant metastases depends on the immune system's ability to eradicate them.The aim of the study is to declare the effect of epidural-intravenous based anesthetic technique on anti-tumor immunity and in comparison to epidural inhalational based anesthetic technique in patients undergoing open surgical resection of colon cancer.
Status | Completed |
Enrollment | 48 |
Est. completion date | August 1, 2020 |
Est. primary completion date | June 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Age 20-70 yrs. - ASA class I and II - Elective open surgery for non-metastatic cancer colon stage I,II Exclusion Criteria: - Patient refusal - Known allergy to the study medications - Patients with compromised immune function ( associated blood diseases, immunosuppressive drugs, chemotherapeutic agents, corticosteroids) - Contraindications to epidural insertion e.g. infection at insertion site and coagulopathy |
Country | Name | City | State |
---|---|---|---|
Egypt | South Egypt Cancer Institute | Assuit |
Lead Sponsor | Collaborator |
---|---|
South Egypt Cancer Institute |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | anti tumour immunity | Venous blood samples are withdrawn. Samples for measurement of percentage of expression of CD8,CD16 and CD56 will be collected in sodium heparin anticoagulant tubes and will be processed according to manufacturer's instructions,and samples for VEGF-C will be centrifuged at 4000 g. Thereafter, the serum will be stored at -22 C for future measurement | preoperative and Day 1 postoperatively | |
Secondary | change in pain intensity | pain intensity measured by Visual analogue scale from 0 to 10 where 0 no pain and 10 is sever pain | 24 hours postoperative |